There are two different points that should be considered in the role of KIR-HLA complex in patients with HCC: the “licensing” of NK cells during maturation, and the control of NK cell activity when stimulated by the activating signal (Figure 1). The gene discussed is KIR3DL1; the disease is hepatocellular carcinoma.